title: Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
abstract: Injection of a dose of haloperidol that has no obvious behavioral effects in normal mice, produces akinesia, catalepsy, and sensory neglect in MPTP-treated mice. Chronic GM1 ganglioside administration improves the behavioral impairments, partially restores striatal dopamine (DA) content and prevents DA D-2 receptor up-regulation. Discontinuation of GM1 ganglioside treatment results in a time-dependent decline of striatal DA content to pretreatment pathological levels, return of haloperidol-induced sensorimotor deficits and a rise of DA D-2 receptor density in the striatum. Apparently, continuous administration of GM1 ganglioside is necessary to maintain the biochemical and behavioral recovery in the MPTP-treated mouse. These observations may provide useful cues for understanding the mechanism of action of GM1 ganglioside.
authors.affiliation: Department of Psychology, College of Social and Behavioral Sciences, Ohio State University, Columbus 43210.
authors.forename: F B
authors.initials: FB
authors.lastname: Weihmuller
authors.forename: M
authors.initials: M
authors.lastname: Hadjiconstantinou
authors.forename: J P
authors.initials: JP
authors.lastname: Bruno
authors.forename: N H
authors.initials: NH
authors.lastname: Neff
mesh_terms: D000818:Animals; D001927:Brain Diseases / Q000503:physiopathology*; D002375:Catalepsy / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000503:physiopathology; D005677:G(M1) Ganglioside / Q000008:administration & dosage / Q000627:therapeutic use*; D006220:Haloperidol / Q000494:pharmacology; D007275:Injections, Intravenous; D020267:MPTP Poisoning; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D009069:Movement Disorders / Q000188:drug therapy / Q000503:physiopathology; D009949:Orientation / Q000187:drug effects; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D017448:Receptors, Dopamine D2; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D005677:G(M1) Ganglioside; D006220:Haloperidol; D004298:Dopamine